Corvus Pharmaceuticals Inc

NASDAQ: CRVS
$9.45
+$0.65 (+7.4%)
Closing Price on November 8, 2024

CRVS Stock Chart and Intraday Price

CRVS Stock Data

Asset Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, US
Fiscal Year End December
Latest Quarter 2023-12-31
Market Cap 88.17M USD
Shares Outstanding 49,038,600
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.

CRVS Articles

Tuesday's Top Wall Street Upgrades and Downgrades: Applied Materials, CVS Health, Hawaiian Electric Industries, Walmart and More
Tuesday's top analyst upgrades and downgrades included Applied Materials, Bill, Catalyst Pharmaceutical, CVS Health, Elastic, Hawaiian Electric Industries and Walmart.
Lee Jackson
Published:

5 White-Hot Stocks Trading Under $10 to Buy Now Have Great Upside Potential
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Lee Jackson
Published:

Wednesday Afternoon's Analyst Upgrades and Downgrades: Lennar, StoneCo, Vertex Energy and More
Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Akamai, Avaya, Canopy Growth, Corsair Gaming, Playtika, Virgin Galactic and More
Wednesday's top analyst upgrades and downgrades included Akamai Technologies, Avaya, Canopy Growth, Corsair Gaming, Skyworks Solutions and Virgin Galactic.
Lee Jackson
Published:
Last Updated: